Cybin Inc. (CYBN) Quarterly EPS earnings growth

cybin.com - graphic logo of issuer CYBN

Demand for innovative molecules from Cybin Inc. (CYBN) is immense due to the failure of conventional antidepressants. Effective fundraising and test transparency support business development. The current quarterly EPS pace on the GURU.Markets dynamic chart reflects operational results, where 33.20 shows the value of this parameter. Cybin Inc. has earned the status of an ethical pioneer by applying a rigorous scientific approach to the therapy of mental disorders.

Cybin (CYBN) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 01/05/2026

Analytical breakdowns and data insights for company Cybin Inc. (CYBN)

- share price and consensus valuation forecast:
Stock Quotes cybin.com|CYBN - Average Forecast Price
- market capitalization details:
Market Capitalization Cybin Corp|CYBN - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share Cybin|CYBN - Accounting Value of Company|Market Value to Book Value Ratio cybin.com|CYBN - Company Assets
- debt and liquidity details:
Total Debt to Capital Cybin Inc.|CYBN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio cybin.com|CYBN - Company Cumulative Debt|Debts to Book Capitalization Cybin Corp|CYBN - Company Long-Term Debt|Company Short-Term Debts Cybin|Quick Liquidity cybin.com
- earnings and valuation multiples indicators:
CYBN - Company Profit|Future Profit Cybin Inc.|CYBN - Company Value to Net Income|Forward P/E Multiple cybin.com|CYBN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cybin Corp|CYBN - Operating profit before amortization|Net earnings per share (EPS TTM) Cybin|CYBN - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months cybin.com|CYBN - Expected net earnings per share growth this year|Earnings growth forecast for next year Cybin Inc.
Comprehensive company analysis:Cybin Inc - CYBN
Flagship merchandise of Cybin

Cybin Inc. focuses on clinical trials, excluding large-scale production and minimizing its environmental footprint. The quarterly EPS change step calculates the quarter-over-quarter earnings per share dynamics, utilizing a normal probability distribution for daily recalculations. The stability of this indicator signals the accumulation of market momentum. A breakout beyond the range boundaries warns of risks of a sharp correction. A sustainable value confirms the fundamental balance of the current valuation.

Direct competitors

ALKS (Alkermes) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Avadel Pharmaceuticals PLC (AVDL)|ATAI (atai Life Sciences Corp) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months GH Research Group (GHRS)|Quarterly EPS earnings growth MNMD|CMPS (compasspathways.com) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months LB Pharmaceuticals LBRX|Bright Minds Bio (DRUG) - Earnings per share growth in annualized terms for the last twelve months|Vanda Pharmaceuticals Inc - Quarterly EPS earnings growth|Alto Neuroscience Corp (ANRO) - Year-over-year net earnings per share growth for the last 12 months|NRXP (NRx Pharmaceuticals) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Cingulate (CING)|SILO (Silo Pharma) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months CPHI|Quarterly EPS earnings growth CMND|Year-over-year net earnings per share change for the last twelve months Psyence Bio|Year-over-year earnings per share growth for the last twelve months SciSparc Ltd SPRC|SEEL: Year-over-year earnings per share growth for the last 12 months|VRPX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KRTX (Karuna Therapeutics Inc)